Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered - Authors' reply

Abstrakt

We appreciate the interest in the publication of "Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease", and we would like to clarify the calculation of the study power.